Terms: = Uterine cancer AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC AND Treatment
92 results:
1. Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer.
D'Agostino E; Mastrodomenico L; Ponzoni O; Baldessari C; Piombino C; Pipitone S; Giuseppa Vitale M; Sabbatini R; Dominici M; Toss A
Cancer Treat Rev; 2024 May; 126():102723. PubMed ID: 38555857
[TBL] [Abstract] [Full Text] [Related]
2. Clonal origin and genomic diversity in Lynch syndrome-associated endometrial cancer with multiple synchronous tumors: Identification of the pathogenicity of mlh1 p.L582H.
Takahashi K; Yachida N; Tamura R; Adachi S; Kondo S; Abé T; Umezu H; Nyuzuki H; Okuda S; Nakaoka H; Yoshihara K
Genes Chromosomes Cancer; 2024 Mar; 63(3):e23231. PubMed ID: 38459936
[TBL] [Abstract] [Full Text] [Related]
3. A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair-deficient and microsatellite instability-high endometrial cancers.
Liu YL; Weigelt B
Cancer; 2024 May; 130(10):1733-1746. PubMed ID: 38422006
[TBL] [Abstract] [Full Text] [Related]
4. Metastasis of endometrial adenocarcinoma masquerading as a primary rectal cancer: A rare case report with literature review.
Li M; Zheng W
Medicine (Baltimore); 2023 Nov; 102(46):e36170. PubMed ID: 37986305
[TBL] [Abstract] [Full Text] [Related]
5. Applicability of the FDA-approved Immunohistochemical Panel for Identification of MMRd Phenotype in uterine Endometrioid Carcinoma.
Adachi S; Kimata JI; Hanami K; Adachi K; Igarashi T; Liang SG; Ishida Y; Fujino T; Yamazaki K
Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):24-31. PubMed ID: 37859432
[TBL] [Abstract] [Full Text] [Related]
6. A retrospective study of consistency between immunohistochemistry and polymerase chain reaction of microsatellite instability in endometrial cancer.
Wang C; Kuang W; Zeng J; Ren Y; Liu Q; Sun H; Feng M; Liang D
PeerJ; 2023; 11():e15920. PubMed ID: 37663290
[TBL] [Abstract] [Full Text] [Related]
7. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
[TBL] [Abstract] [Full Text] [Related]
8. Clinical characteristics and prognostic characterization of endometrial carcinoma: a comparative analysis of molecular typing protocols.
Yang Z; Yang X; Liu X; Ma K; Meng YT; Yin HF; Wen J; Yang JH; Zhen Z; Feng ZH; Liao QP
BMC Cancer; 2023 Mar; 23(1):243. PubMed ID: 36918828
[TBL] [Abstract] [Full Text] [Related]
9. Comparison of Tissue Mismatch Repair Protein Deficiency between Early- and Advanced-Stage Endometrial cancer.
Chaowiwatkun K; Trongwongsa T; Rodpenpear N; Nutthachote P
Asian Pac J Cancer Prev; 2023 Jan; 24(1):345-351. PubMed ID: 36708586
[TBL] [Abstract] [Full Text] [Related]
10. Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia.
Zhang X; Chen D; Zhao X; Wang C; He Y; Chen Y; Wang J; Shen D
Pathol Res Pract; 2023 Jan; 241():154278. PubMed ID: 36580798
[TBL] [Abstract] [Full Text] [Related]
11. Histopathological and molecular findings in 98 cases of endometrial carcinoma: MMR, p53 and next generation sequencing.
Karabağ S; Şentürk M; Söğüt FC; Ergül ÖS; Ersoy T
Pathol Res Pract; 2023 Jan; 241():154275. PubMed ID: 36528987
[TBL] [Abstract] [Full Text] [Related]
12. The statuses of HER2 expression and mismatch repair in endometrial clear cell carcinoma.
Bayramoglu Z; Erozbek SY; Ozdemir IA; Ulker V; Muezzinoglu B
Pathol Res Pract; 2023 Jan; 241():154258. PubMed ID: 36516643
[TBL] [Abstract] [Full Text] [Related]
13. Machine learning applied to MRI evaluation for the detection of lymph node metastasis in patients with locally advanced cervical cancer treated with neoadjuvant chemotherapy.
Arezzo F; Cormio G; Mongelli M; Cazzato G; Silvestris E; Kardhashi A; Cazzolla A; Lombardi C; Venerito V; Loizzi V
Arch Gynecol Obstet; 2023 Jun; 307(6):1911-1919. PubMed ID: 36370209
[TBL] [Abstract] [Full Text] [Related]
14. Microsatellite Instability-High Endometrial cancers with mlh1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles.
Manning-Geist BL; Liu YL; Devereaux KA; Paula ADC; Zhou QC; Ma W; Selenica P; Ceyhan-Birsoy O; Moukarzel LA; Hoang T; Gordhandas S; Rubinstein MM; Friedman CF; Aghajanian C; Abu-Rustum NR; Stadler ZK; Reis-Filho JS; Iasonos A; Zamarin D; Ellenson LH; Lakhman Y; Mandelker DL; Weigelt B
Clin Cancer Res; 2022 Oct; 28(19):4302-4311. PubMed ID: 35849120
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathologic significance of DNA mismatch repair protein status in endometrial cancer.
Kim JH; Kwon BS; Kim H; Suh DH; Kim K; Kim YB; No JH
Taiwan J Obstet Gynecol; 2022 May; 61(3):415-421. PubMed ID: 35595431
[TBL] [Abstract] [Full Text] [Related]
16. Utility of germline multi-gene panel testing in patients with endometrial cancer.
Karpel HC; Chern JY; Smith J M; Smith A J; Pothuri B
Gynecol Oncol; 2022 Jun; 165(3):546-551. PubMed ID: 35483985
[TBL] [Abstract] [Full Text] [Related]
17. The clinical features and management of Lynch syndrome-associated ovarian cancer.
Ran X; Jing H; Li Z
J Obstet Gynaecol Res; 2022 Jul; 48(7):1538-1545. PubMed ID: 35478369
[TBL] [Abstract] [Full Text] [Related]
18. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic cancers.
Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
[TBL] [Abstract] [Full Text] [Related]
19. Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer.
Antill Y; Buchanan DD; Scott CL
Cancer; 2022 Mar; 128(6):1157-1161. PubMed ID: 34875102
[TBL] [Abstract] [Full Text] [Related]
20. Expression of selected molecular factors in two types of endometrial cancer.
Markowska A; Gryboś A; Marszałek A; Bednarek W; Filas V; Gryboś M; Markowska J; Mądry R; Więckowska B; Nowalińska D; Szarszewska M
Adv Clin Exp Med; 2021 Oct; 30(10):1057-1064. PubMed ID: 34510841
[TBL] [Abstract] [Full Text] [Related]
[Next]
